FDA rejects Mylan's generic version of GSK's Advair

(Reuters) - Mylan NV said on Wednesday its application to market a generic copy of GlaxoSmithKline Plc's blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration.